Literature DB >> 8617985

Blockade of platelet endothelial cell adhesion molecule-1 protects against myocardial ischemia and reperfusion injury in cats.

T Murohara1, J A Delyani, S M Albelda, A M Lefer.   

Abstract

Polymorphonuclear leukocytes have been shown to play an important role in myocardial ischemia (MI) and reperfusion (R) injury. Since blockade of platelet-endothelial cell adhesion molecules (PECAM-1) inhibits neutrophil transmigration in vitro and in vivo, the effects of a polygonal Ab directed against PECAM-1 were examined in a feline model of Ml/R. We established cross-reactivity of our anti-human PECAM-1 Ab to cat coronary vasculature and neutrophils by immunohistochemistry and flow cytometry. The anti-PECAM-1 Ab markedly blocked leukocyte transmigration into the peritoneal cavity of cats after glycogen-induced peritonitis. Then, anti-PECAM-1 Ab (1 mg/kg) was tested to determine whether it attenuates MI/R injury in a well characterized feline model of Ml and R. Anti-PECAM-1 Ab administered 10 min before R significantly inhibited the myocardial necrosis seen 4.5 h post-R compared with that in MI/R cats treated with control isotype rabbit IgG (12 +/- 2 vs 29 +/- 4% of area at risk; p less than 0.01) and significantly attenuated the rise in plasma creatine kinase activity (p less than 0.05). The Ab did not prevent increases in cardiac myeloperoxidase activity within the affected regions and did not significantly inhibit autologous neutrophil adhesion to coronary endothelium after stimulation of either neutrophils (by leukotriene B4) or coronary endothelium (by thrombin) in vitro. These results indicate that in vivo blockade of PECAM-1 significantly attenuates MI/R injury, presumably by inhibiting transendothelial migration of neutrophils.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8617985

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization.

Authors:  T Murohara; H Ikeda; J Duan; S Shintani; K i Sasaki; H Eguchi; I Onitsuka; K Matsui; T Imaizumi
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

Review 2.  Endothelial nanomedicine for the treatment of pulmonary disease.

Authors:  Jacob S Brenner; Colin Greineder; Vladimir Shuvaev; Vladimir Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2014-11-14       Impact factor: 6.648

Review 3.  Role of platelet adhesion in homeostasis and immunopathology.

Authors:  D N Männel; G E Grau
Journal:  Mol Pathol       Date:  1997-08

Review 4.  The biology of PECAM-1.

Authors:  P J Newman
Journal:  J Clin Invest       Date:  1997-01-01       Impact factor: 14.808

5.  Depletion of tissue plasminogen activator attenuates lung ischemia-reperfusion injury via inhibition of neutrophil extravasation.

Authors:  Yunge Zhao; Ashish K Sharma; Damien J LaPar; Irving L Kron; Gorav Ailawadi; Yuan Liu; David R Jones; Victor E Laubach; Christine L Lau
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-03-04       Impact factor: 5.464

6.  PECAM-1 and caveolae form the mechanosensing complex necessary for NOX2 activation and angiogenic signaling with stopped flow in pulmonary endothelium.

Authors:  John Noel; Hui Wang; Nankang Hong; Jian-Qin Tao; Kevin Yu; Elena M Sorokina; Kristine Debolt; Michelle Heayn; Victor Rizzo; Horace Delisser; Aron B Fisher; Shampa Chatterjee
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-09-27       Impact factor: 5.464

Review 7.  Nitric oxide and cardioprotection during ischemia-reperfusion.

Authors:  Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2002-10       Impact factor: 4.214

Review 8.  Targeted delivery of therapeutics to endothelium.

Authors:  Eric Simone; Bi-Sen Ding; Vladimir Muzykantov
Journal:  Cell Tissue Res       Date:  2008-09-25       Impact factor: 5.249

9.  Enterocyte shedding and epithelial lining repair following ischemia of the human small intestine attenuate inflammation.

Authors:  Robert A Matthijsen; Joep P M Derikx; Dian Kuipers; Ronald M van Dam; Cornelis H C Dejong; Wim A Buurman
Journal:  PLoS One       Date:  2009-09-15       Impact factor: 3.240

10.  Short-term sPECAM-Fc treatment ameliorates EAE while chronic use hastens onset of symptoms.

Authors:  Emily K Reinke; Jangeun Lee; Alla Zozulya; Jozsef Karman; William A Muller; Matyas Sandor; Zsuzsanna Fabry
Journal:  J Neuroimmunol       Date:  2007-04-27       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.